SCHEMBL3499014

SCHEMBL3499014

Cc1c(C(=O)O)oc2ccc(-c3ccc(Cl)cc3)cc12

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 2/20 0.78
KDM4E B2RXH2 4/20 0.53
GPR35 Q9HC97 1/20 0.53
HPGD P15428 5/20 0.52
GAA P10253 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
NPSR1 Q6W5P4 1/20 0.52
KCNH2 Q12809 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
MAPK1 P28482 1/20 0.50
ALDH1A1 P00352 4/20 0.47
TP53 P04637 1/20 0.46
MAPT P10636 1/20 0.46
CSNK2A2 P19784 1/20 0.46
CSNK2B P67870 1/20 0.46
CSNK2A1 P68400 1/20 0.46
TSHR P16473 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3498475 0.88 MCL1 (0.78) MCL1KDM4EGPR35HPGDGAA
SCHEMBL1444187 0.88 MCL1 (0.63) MCL1KDM4EGPR35HPGDGAA
SCHEMBL4615856 0.88 MCL1 (1.00) MCL1KDM4EGPR35HPGDGAA
SCHEMBL1444097 0.85 MCL1 (0.60) MCL1KDM4EGPR35HPGDGAA
SCHEMBL3499961 0.85 KDM4E (0.61) MCL1KDM4EHPGDSMN1; SMN2KCNH2
SCHEMBL3498056 0.82 KDM4E (0.60) MCL1KDM4EHPGDSMN1; SMN2MEN1
SCHEMBL1444461 0.79 MCL1 (0.59) MCL1KDM4EGPR35HPGDGAA
SCHEMBL1385653 0.78 MCL1 (1.00) MCL1KDM4EGPR35HPGDGAA
SCHEMBL1065472 0.78 MCL1 (0.71) MCL1KDM4EGPR35HPGDGAA
SCHEMBL21858350 0.78 MCL1 (0.80) MCL1KDM4EGPR35HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 MCL1 3727/4885KDM4E 2059/4885GPR35 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.